Wedbush Initiates Coverage On Kalaris Therapeutics with Outperform Rating, Announces Price Target of $17

Benzinga Newsdesk www.benzinga.com Positive 72.4%

Neg 0% Neu 0% Pos 72.4%

Wedbush analyst Yun Zhong initiates coverage on Kalaris Therapeutics (NASDAQ:KLRS) with a Outperform rating and announces Price Target of $17.